Advertisement


Luis G. Paz-Ares, MD, PhD, on NSCLC: Results of the PACIFIC Trial

2017 ESMO Congress

Advertisement

Luis G. Paz-Ares, MD, PhD, of Hospital Universitario 12 De Octubre, discusses phase III study findings on durvalumab after chemoradiation therapy in patients with stage III, locally advanced, unresectable non–small cell lung cancer (Abstract LBA1).



Related Videos

Skin Cancer

Karl D. Lewis, MD, on Melanoma: Results From the BRIM8 Trial

Karl D. Lewis, MD, of the Anschutz Cancer Pavilion, discusses study findings on adjuvant vemurafenib in patients with completely resected BRAF V600–positive melanoma at high risk for recurrence (Abstract LBA7).

Gynecologic Cancers

Sandro Pignata, MD, PhD, on Ovarian and Related Gynecologic Cancers: Expert Perspective on Three Key Trials

Sandro Pignata, MD, PhD, of the Istituto Nazionale dei Tumori, summarizes findings from the ICON8 study on dose-dense chemotherapy integration in first-line epithelial ovarian/fallopian tube/primary peritoneal carcinoma treatment; the ARIEL3 study on rucaparib vs placebo in recurrent ovarian carcinoma; and the ENGOT-OV16/NOVA on quality of life in patients with recurrent ovarian cancer treated with niraparib (Abstracts 929O, LBA40, 930O).

Breast Cancer

Sibylle Loibl, MD, PhD, on Metastatic Breast Cancer: Expert Perspective on CDK4 Inhibitors

Sibylle Loibl, MD, PhD, of the German Breast Group, summarizes a session she chaired in which the rationale to target CDK4, data on efficacy of the inhibitors, and triple combination therapy with PI3K were discussed.

Kidney Cancer

Robert A. Figlin, MD, on RCC: Results From the ADAPT Trial

Robert A. Figlin, MD, of Cedars-Sinai Medical Center, discusses an interim analysis of phase III findings on rocapuldencel-T, an individualized immunotherapy, for newly diagnosed patients with metastatic renal cell carcinoma (Abstract 1137O).

Breast Cancer

Marleen Kok, MD, PhD, on Triple-Negative Breast Cancer: Results From the TONIC Trial

Marleen Kok, MD, PhD, of The Netherlands Cancer Institute, discusses findings from an adaptive phase II noncomparative trial of nivolumab after induction treatment in triple-negative breast cancer (Abstract LBA14).

Advertisement

Advertisement




Advertisement